Navigation Links
OrbusNeich's Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up
Date:5/15/2012

dpoint was non-inferiority based on in-stent late lumen loss at nine months.  The in-stent late lumen loss for the Combo Stent was 0.39 +/- 0.45 mm, compared to 0.44 +/- 0.56 mm for the TAXUS stent. The results were presented late last year during the Late Breaking Clinical Trials and First Report Investigations Session at Transcatheter Cardiovascular Therapeutics (TCT) 2011 in San Francisco. The study's secondary endpoints included clinically driven TLR, binary restenosis, major adverse cardiac events (MACE) and ST rates, as well as all-cause and cardiac mortality, MI and TLF at 30 days, nine months and one through five years.

Ulf Landmesser, M.D., Ph.D., professor of cardiology and head of acute and co-head of invasive cardiology at the Cardiovascular Center, University Hospital of Zurich presented the study design for the REMEDEE OCT trial.

The REMEDEE OCT study will assess vascular healing after deployment of the Combo Stent in patients with acute coronary syndrome (ACS) with single de novo native coronary artery lesions ranging in diameter from greater than or equal to 2.5 mm to less than or equal to 3.5 mm and less than or equal to 20 mm in length. The REMEDEE OCT study, a prospective, multicenter, randomized study, will enroll 60 patients with ACS who will be randomized 1:1 to be treated with the Combo Stent versus the commercially available everolimus eluting stent. The primary endpoint of the study is the percentage of uncovered stent struts per stent at 60 days post procedure determined by OCT. Secondary clinical endpoints include stent thrombosis and major adverse cardiac events (MACE) at 30, 60, 180, 360 and 540 days. MACE is defined as a composite of death, myocardial infarction (MI), emergent coronary artery bypass surgery (CABG), or justified target lesion revascularization (TLR).

"Currently, 55 patients have been enrolled in the REMEDEE OCT study, and we anticipate to complete the enrollment in the next couple of
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Data From REMEDEE Trial Featuring OrbusNeichs Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011
2. Combo method reveals cells signal systems
3. Computer-designed molecules point to new therapy for cystic fibrosis
4. Radiotherapy Clinics of Georgias Founder Returns Home to Celebrate Cancer Survivors and Receive Lifetime Achievement Award
5. Valkee and University of Oulu Publish the First Clinical Trial on Bright Light Therapy Channeled via ear Canals in Seasonal Depression
6. Cell Therapy - Technologies, Markets and Companies
7. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
8. Gene therapy research from Penn Vet & Scheie Eye Inst. cures retinitis pigmentosa in dogs
9. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
10. Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board
11. Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... (PRWEB) July 30, 2014 W. ... the release of the REVELERIS® Prep purification ... chemists, preparative chromatographers, and other researchers to perform ... a single unit. , With the REVELERIS® Prep ... and preparative chromatography modes with a simple touch ...
(Date:7/30/2014)... July 30, 2014  Replikins Ltd. today released new ... Ebola virus. Before the current outbreaks, the mean Ebola ... amino acids) between 1995 and 2002 was 1.1; the ... 2012, and sixteen-fold in 2013, thus predicting the current ... technology has been shown to be able to predict ...
(Date:7/30/2014)... SEGUNDO, Calif. , July 30, 2014 /PRNewswire/ ... contractor on the Fully Integrated Lifecycle Mission Support ... and Space Administration (NASA). Under the terms of ... Ames Research Center at Moffett Field, Calif. In ... support for bioscience flight development projects on the ...
(Date:7/30/2014)... Vycom announces the addition of Thermax ... meet Factory Mutual (FM) 4910 fire propagation and smoke ... benches, process tools, fume hoods, furniture and cabinetry. These ... semiconductor wafers used in electronic chip manufacturing. , ... with excellent workability and superior aesthetics. It is available ...
Breaking Biology Technology:Grace Launches New REVELERIS® Prep Purification System 2Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2
... For the first time, researchers at North Carolina ... whose halves are physically or chemically different ... submarines when an alternating electrical field is applied ... describing the research, published in the Feb. 8, ...
... Feb. 27 Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) ... year ended December 31, 2007., Total revenues in ... $4.7 million in the fourth quarter of 2006. Total ... $19.3 million, compared to $30.6,million in the full year ...
... Feb. 27 /PRNewswire/ -. Mr. Richard W.,Decker II ... the,Edgewood Chemical Biological Center (ECBC) March 2. He ... as Director of Engineering within the,organization since February ... responsible for 1,600 Department,of the Army civilians, soldiers ...
Cached Biology Technology:'2-faced' particles act like tiny submarines 2Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 2Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 3Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 4Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 5Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 6Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 7Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 8Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 9Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 10Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 11Mr. Richard Decker Appointed Technical Director of Edgewood Chemical Biological Center 2
(Date:7/30/2014)... out how to create colors, nature had already perfected ... many different hues, for example. Now scientists are tapping ... way to make colored plastics. Their paper on using ... rather than dyes, to produce color appears in ... Asger Mortensen, Anders Kristensen and colleagues point out that ...
(Date:7/30/2014)... Scientists are searching through a massive collection of ... 50 years ago, and the effort is yielding fresh ... inhabited. , When the collection is fully curated, a ... the largest unbiased Dominican amber collection in the world, ... discovery thus far is that of a pygmy locust, ...
(Date:7/30/2014)... College of Engineering recently received a $330,000 award ... "Nanoparticle-directed synthesis of organic nanorods." , According ... creation and utilization of functional materials, devices, and ... bottleneck in scaling up nanotechnology is the lack ... into one device. A research team led by ...
Breaking Biology News(10 mins):Decades-old amber collection offers new views of a lost world 2NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... German . Interactions between proteins are of ... living cell. However, in order for the proteins to carry ... three-dimensional shape. A number of reactions have been described in ... assume its active structure until the actual binding process commences. ...
... MD, President of the Federation of American Societies for ... continuing support for science and engineering. "The President ... In a letter to President Obama, Talman noted ... time of unprecedented budgetary constraintswill help to improve the ...
... Ore. Researchers at Oregon Health & Science University Doernbecher ... kind of cancer called sarcoma. In a study published today ... , they report that childhood and adult sarcomas are linked ... tumors first start. These findings may lead to non-chemotherapy medicines ...
Cached Biology News:The lock shapes the key 2Scientists discover cell of origin for childhood muscle cancer 2
... Zero Blunt TOPO PCR ... fastest and easiest method ... or equal to95%) cloning ... amplified with proofreading thermostable ...
Quartz-Halogen, 100 W, High Intensity...
... The Baculovirus Expression System with ... recombinant pFastBac™ plasmids containing the polyhedrin ... to the baculovirus genome (bacmid DNA) ... E. coli cells. The recombinant bacmid ...
...
Biology Products: